Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA

Vera Therapeutics, Inc. (NASDAQ:VERA) – Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Vera Therapeutics in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($2.53) per share for the year, down from their previous forecast of ($2.22). The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11.

A number of other equities research analysts have also weighed in on VERA. Wedbush lifted their price objective on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price objective for the company. Wolfe Research started coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price on the stock. Finally, Guggenheim upped their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $64.67.

Vera Therapeutics Trading Down 2.2 %

Shares of Vera Therapeutics stock opened at $29.30 on Thursday. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -11.23 and a beta of 1.17. Vera Therapeutics has a 52-week low of $25.99 and a 52-week high of $51.61. The company’s 50-day simple moving average is $34.70 and its 200-day simple moving average is $40.07. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Insider Activity

In other news, CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $46.94, for a total value of $821,450.00. Following the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at $4,034,117.48. This represents a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 52,500 shares of company stock worth $2,305,625 over the last 90 days. 21.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VERA. Avoro Capital Advisors LLC raised its holdings in shares of Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock worth $237,247,000 after acquiring an additional 1,300,410 shares during the last quarter. Vestal Point Capital LP purchased a new stake in Vera Therapeutics during the 4th quarter worth about $45,462,000. Lord Abbett & CO. LLC raised its stake in Vera Therapeutics by 170.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company’s stock valued at $48,788,000 after purchasing an additional 727,656 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Vera Therapeutics by 162.2% in the 4th quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company’s stock valued at $45,926,000 after purchasing an additional 671,881 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its holdings in Vera Therapeutics by 130.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company’s stock valued at $48,634,000 after purchasing an additional 650,000 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.